3-(Chloromethyl)-4-(4-hydroxybenzylidene)isoxazol-5(4H)-one

Catalog No. :
ACLVAO755
CAS No. :
1142199-72-1
Molecular Formula :
C11H8ClNO3
Molecular Weight :
237.64

IUPAC Name:(E)-3-(chloromethyl)-4-(4-hydroxybenzylidene)isoxazol-5(4H)-one

3-(Chloromethyl)-4-(4-hydroxybenzylidene)isoxazol-5(4H)-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$124.00Login to see priceInquiryInquiry
5g95%$373.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(Chloromethyl)-4-(4-hydroxybenzylidene)isoxazol-5(4H)-one
IUPAC Name(E)-3-(chloromethyl)-4-(4-hydroxybenzylidene)isoxazol-5(4H)-one
MDL No.MFCD12027823
Molecular FormulaC11H8ClNO3
Molecular Weight237.64
SMILESO=C1ON=C(CCl)/C1=C\C1=CC=C(O)C=C1
InChI KeyNRXWYEXYHHJRFQ-WEVVVXLNSA-N
Synonym(4E)-3-(chloromethyl)-4-(4-hydroxybenzylidene)isoxazol-5(4H)-one;3-(chloromethyl)-4-[(4-hydroxyphenyl)methylidene]-1,2-oxazol-5-one;3-(Chloromethyl)-4-(4-hydroxybenzylidene)isoxazol-5(4H)-one;5(4H)-Isoxazolone, 3-(chloromethyl)-4-[(4-hydroxyphenyl)methylene]-
CAS No.1142199-72-1

Safety Data

Pictogram
CorrosiveHarmful or irritant
Signal Word
Gefahr
Hazard Statement(s)
H302-H314
Precautionary Statement(s)
P264-P270-P271-P280-P303+P361+P353-P304+P340-P305+P351+P338-P310-P330-P331-P363-P403+P233-P501

Synthetic Route by SureRoute

1. ACLVAO755 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRZDC412 route compound structure diagram
    ACRZDC412123-08-0 In Stock
  4. Then
  5. ACLVAO755 route product structure diagram
    ACLVAO7551142199-72-1
Inquiry

2. ACLVAO755 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLVAO755 route product structure diagram
    ACLVAO7551142199-72-1
Inquiry

Comments (0)